Skip Ribbon Commands
Skip to main content
Menu

Clinical Services

The SPRinT team sees patients with a wide spectrum of cancer types as peritoneal surface malignancies can arise from various organs. They can arise primarily from the peritoneum (e.g. mesothelioma, primary peritoneal cancer) or from the spread of a primary cancer (e.g. colorectal, appendix, stomach, ovary, hepatobiliary). Our team has extensive experience in treating these varieties of cancer from early to advanced stages.

Gastrointestinal and Peritoneal Surface Malignancies

The peritoneum is a thin membrane that lines the abdominal and pelvic cavities, covering the external surface of most of the abdominal organs. Peritoneal surface malignancy refers to a wide variety of cancers that involve the peritoneum and may also involve other abdominal organs such as spleen, large and small intestines, stomach, the liver and the pelvic organs. The tumours may arise from the lining itself or may spread to the lining from other organs.

Previously regarded as fatal, peritoneal disease of all histological subtypes can now be successfully treated to achieve good outcomes for patients. Our multidisciplinary clinics offer a one-stop service for the evaluation and surgical management of these patients. In conjunction with our medical oncologists, we provide a comprehensive range of treatments for patients with peritoneal disease, including cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

The SPRinT team has been performing CRS and HIPEC since 2001 and currently, has one of the most extensive experience in Asia for CRS and HIPEC for patients with peritoneal-based cancers. The team is also dedicated to pushing the boundaries of clinical care and is involved in numerous clinical trials, including the use of pressurized intraperitoneal aerosol chemotherapy (PIPAC) and prophylactic HIPEC for the treatment of selected patients. Novel therapeutic strategies including the use of small molecule inhibitors and delivery of chemotherapeutics are actively researched and implemented in our unit.

Find out more about PIPAC

Sarcomas

Soft tissue sarcomas are a group of rare cancers that affect the soft tissues of the body. There are more than 70 different subtypes of soft tissue sarcomas, of which the more common ones are liposarcomas, leiomyosarcomas, solitary fibrous tumors, malignant peripheral nerve sheath tumors, among others. Combining the latest evidence and collaborating with specialists from all relevant specialties, the SPRinT team provides a comprehensive diagnostic and therapeutic service for this rare disease. We are the most experienced unit performing multi-visceral resections for all forms of sarcoma in Singapore and is one of the few experienced tertiary referral units in Asia dealing with this debilitating disease.

Skin Cancers

Skin cancers provide a diagnostic and therapeutic dilemma for most clinicians. Accurate diagnosis and staging is crucial to ensure good outcomes. The SPRinT team works closely with our pathologists and medical oncologists to diagnose and treat various skin malignancies. We perform advanced surgical resections with reconstruction, achieving locoregional staging with sentinel lymph node biopsies, and control via lymph node dissections. We also perform isolated limb perfusion when necessary. With advancements in the use of biologics and immunotherapy for skin malignancies, the SPRinT team constantly combines surgery with novel chemotherapeutics to provide the most up to date treatment for patients.

Advanced Intra-abdominal Malignancies

Many patients with advanced intra-abdominal malignancies often present a conundrum for the clinical team as the disease does not fall into clearly defined diagnostic groups. Our surgical oncologists in the SPRinT team perform complex multi-visceral and pelvic exenterations for locally advanced intra-abdominal malignancies; working hand-in-hand with medical and radiation oncologists to employ useful neo-adjuvant and adjuvant treatments when necessary. For example, gastrointestinal tumours (GISTs) with acquired resistance to biologics are resected routinely by our team in close consultation with the medical oncology team.